In Vietnam, lung cancer has one of the highest death rates, with non-small-cell lung carcinoma accounting for 85% of patients being treated. On August 31st 2019, Ho Chi Minh City Oncology Hospital cooperated with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, to hold a Scientific Seminar About Diagnosing and Treating Non-Small-Cell Lung Carcinoma Having EGFR Mutation for doctors to discuss and share their experiences in treating the condition.
The seminar took place formally in Nikko Saigon Hotel, District 1, Ho Chi Minh City, with the role of chairman being run by Ph.D Dr Pham Xuan Dung, Director of Ho Chi Minh City Oncology Hospital and Ph.D Dr Le Thuong Vu, Vice Head of Pulmonary Department at Cho Ray Hospital. The presenters who took part of the talk included; M.D Dr Shanop ShuangShoti, Chulalongkorn University Hospital, Thailand; M.D Dr Nguyen Son Lam, Pham Ngoc Thach Hospital; Dr Basma M’Barek, Hy Vong Cancer Care Centre, FV Hospital; and Dr Nguyen Tuan Khoi, Ho Chi Minh City Oncology Hospital; with more than 100 guests comprising of high-level doctors in many hospitals across the city.
Attending the seminar, Dr Basma M’Barek, Hy Vong Cancer Care Centre from FV Hospital, shared her experiences on the topic Optimizing When Using Osimertinib in Treating Non-Small-Cell Lung Carcinoma NSCLC & Sharing Treated Cases. Basma’s presentation took documents from successfully treated cases at Hy Vong Cancer Centre, which really engaged the audience. A Q&A session was held after the talk where guests asked numerous questions to receive advice and hear about the steps of diagnosis and treatment.
Hearing specific techniques and how to put them into practice from Dr Basma M’Barek, Hy Vong Cancer Care Centre, FV Hospital, as well as other medical professions, contributed to the success of the seminar. FV Hospital prides itself on treating this condition and is always keen to contribute to the Vietnamese medical community by giving advice on diagnosing and treating non-small-cell lung carcinoma.
